Blog Band - Page 26 of 299

19

Shots: The US FDA has approved Tonmya (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults; commercially available in Q4’25 Approval was based on 2 P-III (RELIEF &…

19

Aug 2025

NEWS

RemeGen Enters a Licensing Agreement with Santen Pharmaceutical for RC28-E to Treat Eye Diseases

Shots: RemeGen has granted Santen exclusive rights to develop, manufacture, & commercialize RC28-E in Greater China (incl. Mainland China, Hong Kong, Macau, & Taiwan), South Korea, Thailand, Vietnam, Singapore, Philippines,…

19

Aug 2025

NEWS

Boehringer Ingelheim Joins Forces with Palatin to Develop Novel Therapies for Retinal Diseases

Shots: BI has entered into a global research collaboration and licensing agreement with Palatin Technologies to develop novel melanocortin receptor agonist for retinal diseases As per the deal, Palatin is…

19

Aug 2025

NEWS

Skyhawk Therapeutics Enters a ~$2B Deal with Merck KGaA to Identify RNA-Targeting Small Molecules for Neurological Disorders

Shots: Skyhawk Therapeutics has entered into a strategic research collaboration with Merck KGaA to discover novel RNA-targeting small molecules for neurological diseases with limited treatment options Skyhawk will receive ~$2B incl.…

19

Aug 2025

NEWS

SpringWorks Therapeutics (Merck KGaA) Reports the EC’s Approval of Ogsiveo (Nirogacestat) for Desmoid Tumors

Shots: The EC has approved Ogsiveo as a monotx. for adults with progressing desmoid tumors needing systemic treatment Approval was based on global P-III (DeFi) trial (N=142) assessing Ogsiveo (150mg,…

18

Aug 2025

VIEWPOINTS

Awareness Campaign: Catherine Frenette from Gilead in Conversation with PharmaShots

Shots: At this year’s European Association for the Study of the Liver (EASL) Congress in Amsterdam, Gilead shared new data and 29 abstracts, including three oral presentations. But the data…

18

Aug 2025

NEWS

SystImmune and BMS’ Izalontamab Brengitecan Secures the US FDA’s Breakthrough Therapy Designation to Treat EGFRm NSCLC

Shots: The US FDA has granted BTD to izalontamab brengitecan (iza-bren) for LA/M NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations progressing on or after EGFR TKI…

18

Aug 2025

VIDEO

LIFE SCIENCES | DAILY NEWS | AUG 18, 2025 | PHARMASHOTS

18

Aug 2025

NEWS

Galvanize Therapeutics Enrolls First Patient in PROPEL Registry Trial of Aliya Pulsed Electric Field Ablation for Soft Tissue Lesions

Shots: Galvanize Therapeutics has enrolled the first patient in the PROPEL registry trial evaluating the Aliya Pulsed Electric Field ablation system for soft tissue lesions, including primary and metastatic lung,…

18

Aug 2025

NEWS

Valneva Obtains Health Canada’s Approval for Ixchiq to Prevent Chikungunya

Shots: Health Canada has approved label expansion for Ixchiq against CHIKV disease in individuals (≥12yrs.) Approval was based on a P-III trial of Ixchiq vs PBO in adolescents over 6mos.,…

Tonix Pharmaceuticals’ Tonmya Receives the US FDA’s Approval for Fibromyalgia

Boehringer Ingelheim Joins Forces with Palatin to Develop Novel Therapies for Retinal Diseases

Skyhawk Therapeutics Enters a ~$2B Deal with Merck KGaA to Identify RNA-Targeting Small Molecules for Neurological Disorders

SpringWorks Therapeutics (Merck KGaA) Reports the EC’s Approval of Ogsiveo (Nirogacestat) for Desmoid Tumors

Awareness Campaign: Catherine Frenette from Gilead in Conversation with PharmaShots

SystImmune and BMS’ Izalontamab Brengitecan Secures the US FDA’s Breakthrough Therapy Designation to Treat EGFRm NSCLC

LIFE SCIENCES | DAILY NEWS | AUG 18, 2025 | PHARMASHOTS

Galvanize Therapeutics Enrolls First Patient in PROPEL Registry Trial of Aliya Pulsed Electric Field Ablation for Soft Tissue Lesions

Valneva Obtains Health Canada’s Approval for Ixchiq to Prevent Chikungunya

Contact US

OUR INFORMATION

FOLLOW US